Cognitive vitality.
Genetically validated.
Powering the potential oF Klotho
We are all born with a gene for producing the Klotho protein, though some produce more than others. This protein circulates in the blood, protecting the brain and reducing toxicity. However, chronic stress and aging deplete it. But what if we could replenish it?
Around 1 in 4 people carry the KL-VS allele, which boosts circulating Klotho levels, enhances cognitive function, and lowers the risk of Alzheimer’s and other neurodegenerative diseases. KL-VS even helps mitigate risk for APOE4 carriers.
Primate research confirms the promise of Klotho
When given a physiologic dose of Klotho protein, non-human primages, who age and decline in a parallel fashion to humans, show significant improvement in working memory that is immediate and lasts several weeks after a single injection.
More Klotho enhances cognition and performance. Compare cognitive test results averaged for KL-VS Klotho carriers (n=188) vs. non-carriers (n=530).
JN-0413
poised to take the next step
At Jocasta, we are focused on the therapeutical potential of Klothoto ultimately improving how we age. Klotho JN-04133, our proprietary synthetic subcutaneous formulation, is a first-in-class, best-in-class treatment.
We are enthusiastically awaiting human trials, estimated to begin in 2026, pending ongoing manufacturing.
RECENT NEWS
